Histological Typing Of Lung And Pleural Tumours

with contributions by Pathologists from 14 Countries

WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart is the seventh volume in the Fourth Edition of the WHO series on histological and genetic typing of human tumors. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome.

****When not purchasing directly from the official sales agents of the WHO, especially at online bookshops, please note that there have been issues with counterfeited copies. Buy only from known sellers and if there are quality issues, please contact the seller for a refund.***** Thoracic Tumoursis the fifth available volume in the fifth edition of the WHO series on the classification of human tumours. This series (also known as the WHO Blue Books) is regarded as the gold standard for the diagnosis of tumours and comprises a unique synthesis of histopathological diagnosis with digital and molecular pathology. These authoritative and concise reference books provide indispensable international standards for anyone involved in the care of patients with cancer or in cancer research, underpinning individual patient treatment as well as research into all aspects of cancer causation, prevention, therapy, and education. What's new in this edition? The fifth edition, guided by the WHO Classification of Tumours Editorial Board, establishes a single coherent cancer classification presented across a collection of individual volumes organized on the basis of anatomical site (digestive system, breast, soft tissue and bone, etc.) and structured in a systematic manner, with each tumour type listed within a taxonomic classification: site, category, family (class), type, and subtype. In each volume, the entities are now listed from benign to malignant and are described under an updated set of headings, including histopathology, diagnostic molecular pathology, staging, and easy-to-read essential and desirable diagnostic criteria. Who should read this book? * Pathologists * Oncologists * Respiratory physicians * Thoracic radiologists * Cancer researchers * Surgeons * Epidemiologists * Cancer registrars This volume: * Prepared by 217 authors and editors * Contributors from around the world * More than 1000 high-quality images * More than 3500 references

This series on the treatment of cancer is sponsored by the UICe. The editors and authors feel strongly that more standar dization in cancer therapy is needed on a worldwide basis. This, of course, is only possible if experts from all countries subscribe to a joint policy of making their treatment designs available to practising oncologists all over the world. Current Treatment of Cancer discusses all the equipment and methods now in use in cancer therapy. It covers all types of cancer, thus providing the reader with comprehensive infor mation on cancer management. In recent decades there has been a tremendous improve ment in the treatment of cancer, and there is hope for even fur ther success in this fight. We are convinced that this series will help us to make a concerted response to the challenge of can cer. UICC Treatment and Rehabilitation Programme Ismail Elsebai Chairman Preface Part I Members of two institutions, the Brompton Hospital in London and the Finsen Institute in Copenhagen, were invited to write on lung cancer, and after reading the manuscripts it was decided that the contents of three pairs of chapters overlapped sufficiently for them to be combined.

Based on the author's experience through 40 years of work with lung cancers, this resource is based on the theme that carcinomas of the lung have overlapping characteristics, with quantitative rather than qualitative differences. It contains photographs depicting characteristic growth patterns, and complications such as cavitation and exsanguination. Coverage includes gross pathology and the defining histopathology; the neuroendocrine tumours; adenocarcinomas; large cell carcinomas; adenosqaumous carcinomas; mesotheliomas; benign tumours; and tumour-like lesions, including hamartomas, eosinophilic granulomas, sclerosing hemangiomas and inflammatory pseudotumours.